[Form 3] First Wave BioPharma, Inc. Common Stock Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Director Geordan G. Pursglove filed an initial Form 3 reporting no beneficial ownership of the issuer's securities. The filing lists the reporting person as a Director and indicates the event date as 08/11/2025. The document shows the reporting person has no direct or indirect holdings in the company at the time of the statement and includes a manual signature dated 08/18/2025.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pursglove Geordan Garrett

(Last) (First) (Middle)

C/O ENTERO THERAPEUTICS, INC.

777 YAMATO ROAD, SUITE 502

(Street)

BOCA RATON FL 33431

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
Entero Therapeutics, Inc. [ ENTO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Geordan G. Pursglove	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Entero Therapeutics (ENTO) report?

The Form 3 filed by Geordan G. Pursglove reports no securities beneficially owned as of the filing.

What is the reporting person's relationship to Entero Therapeutics in this Form 3?

The form identifies the reporting person as a Director of Entero Therapeutics.

What dates are shown on the Form 3 for ENTO?

The event date is 08/11/2025 and the signature date is 08/18/2025.

Does the Form 3 list any derivative or non‑derivative securities owned?

No. The filing explicitly states "No securities are beneficially owned."

Was the Form 3 filed by one person or jointly?

The form is marked as filed by one reporting person.